Page last updated: 2024-11-05

pivalic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pivalic acid: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pivalic acid : A branched, short-chain fatty acid composed of propanoic acid having two methyl substituents at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6417
CHEMBL ID322719
CHEBI ID45133
SCHEMBL ID3613
MeSH IDM0047205

Synonyms (80)

Synonym
dimethylpropionic acid
2,2-dimethylpropionic acid
2,2-dimethylpropanoic acid
wln: qvx1&1&1
neopentanoic acid
nsc65449
nsc-65449
.alpha.,.alpha.-dimethylpropionic acid
tert-pentanoic acid
acetic acid, trimethyl-
versatic 5
propionic acid, 2,2-dimethyl-
einecs 200-922-5
nsc 65449
kyselina pivalova [czech]
hsdb 5211
kyselina 2,2-dimethylpropionova [czech]
ai3-04165
brn 0969480
inchi=1/c5h10o2/c1-5(2,3)4(6)7/h1-3h3,(h,6,7
pivalic acid
propanoic acid, 2,2-dimethyl-
trimethylacetic acid
75-98-9
pivalic acid, 99%
acido pivalico
pivalinsaeure
CHEBI:45133 ,
acide 2,2-dimethylpropanoique
alpha,alpha-dimethylpropionic acid
acide pivalique
LMFA01020073
2,2-dimethyl-propanoic acid
CHEMBL322719
2,2-dimethyl-propionic acid
FT-0656670
P0461
AKOS000119013
A838577
NCGC00248606-01
dtxcid106432
tox21_200425
cas-75-98-9
dtxsid8026432 ,
NCGC00257979-01
piv ,
ec 200-922-5
4-02-00-00908 (beilstein handbook reference)
unii-813re8bx41
kyselina 2,2-dimethylpropionova
813re8bx41 ,
kyselina pivalova
pivalic acid [mi]
2,2-dimethylpropanoic acid [hsdb]
STL264139
BP-30032
SCHEMBL3613
tert-c4h9cooh
neovaleric acid
pivaloic acid
2,2,-dimethylpropionic acid
pivoh
2,2,2-trimethylacetic acid
tert-butyl carboxylic acid
trimethyl acetic acid
5-iodo-mono-methylisophthalate
pivalic acid;
pvalc acd
J-523981
F2191-0097
mfcd00004194
pivalinsaure
trimethyl-acetic acid
pivalic acid (acd/name 4.0)
CS-D1464
Q421509
STR05697
D78007
BAA18488
EN300-21285

Research Excerpts

Overview

Pivalic acid is a short-chain, branched carboxylic acid used to increase oral bioavailability of prodrugs. Antibiotics containing pivalic Acid are frequently used as wide spectrum antibiotics for pediatric patients in Japan.

ExcerptReferenceRelevance
"Pivalic acid is a substance used in prodrugs to increase absorption of parent drugs, and antibiotics containing pivalic acid are frequently used as wide spectrum antibiotics for pediatric patients in Japan."( Hypocarnitinemia Observed in an Infant Treated with Short-Term Administration of Antibiotic Containing Pivalic Acid.
Fuchigami, T; Ishige, M; Ishige, N; Nakazaki, K; Ogawa, E; Takahashi, S, 2018
)
1.42
"Pivalic acid is a short-chain, branched carboxylic acid used to increase oral bioavailability of prodrugs."( Preclinical evaluation of 3-18F-fluoro-2,2-dimethylpropionic acid as an imaging agent for tumor detection.
Aboagye, EO; Alam, IS; Brickute, D; Gottlieb, E; Kaliszczak, M; Nguyen, QD; Pisaneschi, F; Schug, Z; Trousil, S; Twyman, F; Witney, TH, 2014
)
1.12

Treatment

Treatment with pivalic acid or sodium pivalate did not render male hamsters infertile. It appeared to reduce the fertilizing ability of their spermatozoa.

ExcerptReferenceRelevance
"Treatment with pivalic acid containing prodrugs has been shown to cause carnitine depletion by loss of pivaloyl carnitine in urine. "( Effect of short-term treatment with pivalic acid containing antibiotics on serum carnitine concentration--a risk irrespective of age.
Abrahamsson, K; Holme, E; Jodal, U; Lindstedt, S; Nordin, I, 1995
)
0.92
"Treatment with pivalic acid or sodium pivalate did not render male hamsters infertile although it appeared to reduce the fertilizing ability of their spermatozoa."( Effects of pivalic acid and sodium pivalate on L-carnitine concentrations in the cauda epididymidis and on male fertility in the hamster.
Cooper, T; Fournier-Delpech, S; Golan, R; Lewin, LM; Pholpramool, C; Shochat, L; Weissenberg, R, 1997
)
1.03

Toxicity

ExcerptReferenceRelevance
" This study indicated that there was a decrease in free carnitine levels in plasma, but there were no clinical symptoms or adverse effects associated with carnitine reduction in patients during the 7-day multiple administration of S-1108."( Carnitine status and safety after administration of S-1108, a new oral cephem, to patients.
Fujita, Y; Hiraga, Y; Inamatsu, T; Nishikawa, T; Ohmichi, M; Saito, A; Shimada, J; Shimada, K; Shimizu, K; Tanimura, M, 1993
)
0.29
" As carnitine conjugation is thought to be the only detoxification metabolic route in canine muscle, under certain circumstances such as carnitine deficiency, the risk of exposure with toxic pivaloyl CoA might increase and the CoASH pool in canine muscle might be exhausted, resulting in toxicity in canine muscle."( Possible mechanism for species difference on the toxicity of pivalic acid between dogs and rats.
Nakajima, Y; Nakamura, Y; Yamaguchi, T, 2006
)
0.58

Bioavailability

Pivalic acid is a short-chain, branched carboxylic acid used to increase oral bioavailability of prodrugs. Some oral cephem antibiotics have pivalic Acid side chain to increase absorption rate at intestine.

ExcerptReferenceRelevance
"In an effort to improve the oral bioavailability of naltrexone [17-(cyclopropylmethyl)-4,5 alpha-epoxy-3,14-dihydroxymorphinan-6-one;1], a number of prodrug esters on the 3-hydroxyl group were prepared: the anthranilate (2), acetylsalicylate (3), benzoate (4), and pivalate (5)."( Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach.
Hussain, MA; Koval, CA; Myers, MJ; Shami, EG; Shefter, E, 1987
)
0.27
"Prodrugs that liberate pivalate (trimethylacetic acid) after hydrolysis have been developed to improve the bioavailability of therapeutic candidates."( Pivalate-generating prodrugs and carnitine homeostasis in man.
Brass, EP, 2002
)
0.31
" Some oral cephem antibiotics have pivalic acid side chain to increase absorption rate at intestine."( Children's toxicology from bench to bed--Liver injury (1): Drug-induced metabolic disturbance--toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism.
Ito, T, 2009
)
0.83
" Pivalic acid is a short-chain, branched carboxylic acid used to increase oral bioavailability of prodrugs."( Preclinical evaluation of 3-18F-fluoro-2,2-dimethylpropionic acid as an imaging agent for tumor detection.
Aboagye, EO; Alam, IS; Brickute, D; Gottlieb, E; Kaliszczak, M; Nguyen, QD; Pisaneschi, F; Schug, Z; Trousil, S; Twyman, F; Witney, TH, 2014
)
1.31

Dosage Studied

ExcerptRelevanceReference
" The concentration of radioactivity in the liver, cortex of the kidney, and skeletal muscle 144 h after oral dosing was more than 10 times higher than the concentration in plasma for all doses."( Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C]S-1108 in rats and dogs.
Futaguchi, S; Katsuyama, Y; Mizojiri, K; Nagasaki, T; Nakanishi, M; Norikura, R; Yoshimori, T, 1995
)
0.52
" When the dosing was terminated, pivaloylcarnitine in plasma and then in urine disappeared, and the concentration of free carnitine, acyl/free carnitine ratio returned to the normal range."( [Effect of cefditoren pivoxil on carnitine metabolism in pediatric patients].
Chiba, S; Fujii, R; Meguro, H; Mori, A; Mori, T; Numazaki, K; Satoh, Y; Sunakawa, K; Terashima, I; Toyonaga, Y, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
short-chain fatty acidAn aliphatic monocarboxylic acid with a chain length of less than C6. If any non-hydrocarbon substituent is present, the compound is not normally regarded as a short-chain fatty acid.
branched-chain saturated fatty acidAny saturated fatty acid with a carbon side-chain or isopropyl termination.
methyl-branched fatty acidAny branched-chain fatty acid containing methyl branches only.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency0.61440.000714.592883.7951AID1259369
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency24.46030.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency35.07050.000817.505159.3239AID1159527; AID1159531
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Free fatty acid receptor 3Rattus norvegicus (Norway rat)EC50 (µMol)500.00005.00005.00005.0000AID1341023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID94989Effect of compound on erythroid differentiation of K562 cells was determined after a period of 9 days at concentration 4 mM1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Induction of erythroid differentiation of human K562 cells by 3-O-acyl-1,2-O-isopropylidene-D-glucofuranose derivatives.
AID94965Evaluated for erythroid induction of benzidine-positive K562 cells at concentration 3 mM1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Induction of erythroid differentiation of human K562 cells by 3-O-acyl-1,2-O-isopropylidene-D-glucofuranose derivatives.
AID94981Effect of compound on erythroid differentiation of K562 cells was determined after a period of 5 days at concentration 4 mM1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Induction of erythroid differentiation of human K562 cells by 3-O-acyl-1,2-O-isopropylidene-D-glucofuranose derivatives.
AID94985Effect of compound on erythroid differentiation of K562 cells was determined after a period of 7 days at concentration 4 mM1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Induction of erythroid differentiation of human K562 cells by 3-O-acyl-1,2-O-isopropylidene-D-glucofuranose derivatives.
AID94977Effect of compound on erythroid differentiation of K562 cells was determined after a period of 3 days at concentration 4 mM1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Induction of erythroid differentiation of human K562 cells by 3-O-acyl-1,2-O-isopropylidene-D-glucofuranose derivatives.
AID1750491Reduction of propionyl-CoA in human hepatocytes derived from propionic acidemia patient at 100 uM pretreated for 30 mins followed by 13C-isoleucine addition and measured after 1 hr by MS/MS analysis relative to control2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia.
AID1750492Reduction of propionyl-CoA in human hepatocytes derived from propionic acidemia patient pretreated for 30 mins followed by 13C-isoleucine addition and measured after 1 hr by MS/MS analysis2021Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8
Identification of 2,2-Dimethylbutanoic Acid (HST5040), a Clinical Development Candidate for the Treatment of Propionic Acidemia and Methylmalonic Acidemia.
AID95143Inhibition of cell growth against human myeloid leukemia K562(S) cells1999Bioorganic & medicinal chemistry letters, Nov-01, Volume: 9, Issue:21
Induction of erythroid differentiation of human K562 cells by 3-O-acyl-1,2-O-isopropylidene-D-glucofuranose derivatives.
AID682299TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Pivalate: 500 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (110)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (10.00)18.7374
1990's35 (31.82)18.2507
2000's34 (30.91)29.6817
2010's27 (24.55)24.3611
2020's3 (2.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.67 (24.57)
Research Supply Index4.74 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index85.03 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.79%)5.53%
Reviews7 (6.25%)6.00%
Case Studies4 (3.57%)4.05%
Observational0 (0.00%)0.25%
Other99 (88.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]